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MicroRNAs (miRNAs) are small 22–24 nucleotide non-
coding RNA molecules that regulate gene expression by
hybridization to 30 untranslated regions (30 UTRs) of target
messenger RNAs (mRNAs) resulting in their degradation or
translational inhibition1. Collectively more than 4000 miRNA
sequences exist in a wide range of species of which more than
700 are encoded by the human genome2. Of the latter, some
150–200 are expressed in the heart where they are dynamically
regulated in response to cardiac disease3.
MiRNAs constitute a particularly abundant and funda-
mental class of regulators of gene expression. Apart from their
involvement in developmental aspects of higher organisms,
they are now implicated in an increasing number of physio-
logical processes. Initially, miRNAs were shown to play
important roles in plant biology4, viral diseases5, develop-
mental processes6 and cancer7. More recently, several studies
have demonstrated their importance in the regulation of
cardiac development8 and various cardiovascular diseases such
as myocardial infarction9, cardiac hypertrophy10 and heart
failure11.
The heart responds to injury and hemodynamic overload
by promoting myocyte hypertrophy, reexpressing a fetal gene
program and remodeling the extracellular matrix. Speciﬁc
miRNAs are disregulated in the diseased heart and, in mice,
up- and down-regulation of miRNAs have been found to be
necessary and sufﬁcient to explain diverse heart diseases12.
Thus, normalizing miRNA expression in the heart represents a
new approach to the pharmacotherapy of heart disease13–15.
In this paper, we review miRNA biology in general and
the literature relating to the mechanisms of miRNA action in
cardiac hypertrophy, myocardial ﬁbrosis and heart failure.
Understanding how miRNAs regulate not only single
genes but the whole gene network has enormous therapeutic
implications.2. MiRNA biogenesis and biological function
MiRNAs are encoded in the genomes of plants and animals.
They are initially transcribed by RNA polymerase II or, in a
few cases, RNA polymerase III as long primary miRNAs
(pri-miRNAs) containing a 65-nucleotide stem loop16.
Pri-miRNAs fold into hairpin structures containing imperfectly
base-paired stems and are processed by the endonuclease
Drosha and its cofactor DiGeorge syndrome critical region 8
(dgcr8) into 60–100 nt hairpins known as pre-miRNAs17,18.
Pre-miRNAs are then exported to the cytoplasm by Exportin-5
and subsequently processed by the cytoplasmic RNaseIII,
Dicer, which also resides in a multiprotein complex19.
Cleavage of the pre-miRNA by Dicer produces mature
miRNAs, which are incorporated into the RNA-induced
silencing complex (RISC). This then recognizes speciﬁc targets
and induces post-transcriptional gene silencing through bind-
ing of the mature miRNA to the 30 untranslated region of its
target mRNA through exact and partial complementarity20.
Depending on the overall degree of complementarity, gene
silencing occurs through either inhibition of translation or
degradation of its target mRNAs. Interestingly, in rare cases,
miRNAs have also been reported to stimulate mRNA transla-
tion21, a ﬁnding which has sparked controversy and led todemands for more research into the mechanisms by which
miRNAs regulate gene expression22.3. MiRNAs and cardiac hypertrophy
Cardiac hypertrophy is an important compensatory mechan-
ism of the heart in response to diverse pathophysiological
stimuli. Initially, the response aims to normalize wall stress
and preserve contractile performance but chronically it pro-
duces hypertrophy and may eventually lead to heart failure.
Although various pathways provide coordinated control of
the hypertrophic process, little is known about their under-
lying molecular mechanisms. Exposure of the heart to some
stressors may lead to cardiac remodeling with a change in the
gene expression proﬁle and a detrimental outcome. The
involvement of miRNAs in this pathological process is now
recognized and increasing evidence shows that miRNAs are
key modulators of cardiovascular development and function
and the process of cardiac hypertrophy.
Number of miRNAs are found to be regulated during
cardiac hypertrophy and two, miR-1 and miR-133, play a key
role in inhibiting it. MiR-1 and miR-133 are included in the
same bicistronic unit and are speciﬁcally expressed in skeletal
muscle and cardiac myocytes8. Embryonic overexpression of
miR-1 in vivo results in thin-walled ventricles, whereas miR-1
knockout mice display chambers with thickened walls23. MiR-
1 is down-regulated at the onset of pressure overload on the
heart that appears to be sufﬁcient to account for the changes
in gene expression underlying the initiation and progression of
cardiac hypertrophy24. MiR-1 down-regulates calcium–
calmodulin signaling through the calcineurin/NFAT pathway
and negatively regulates the expression of Mef2a and Gata4 to
inhibit cardiomyocyte growth25. The cytoskeleton regulatory
protein, twinﬁlin-1, is a novel target of miR-1 and reduction of
miR-1 by hypertrophic stimuli up-regulates twinﬁlin-1 which,
in turn, evokes hypertrophy through regulation of the cardiac
cytoskeleton26.
MiR-133 has a critical role in determining cardiomyocyte
hypertrophy; its overexpression inhibits hypertrophy whereas
its suppression induces hypertrophy both in vitro and in vivo10.
Recently, Dong et al.27 found miR-133 expression was down-
regulated, and calcineurin activity enhanced in both in vivo
and in vitro models of cardiac hypertrophy27. In addition, they
found that using cyclosporine A to inhibit calcineurin pre-
vented the down-regulation of miR-133 in cardiac hypertrophy.
These results indicate that miR-133 and calcineurin are reci-
procally repressed in cardiac hypertrophy. Moreover, another
study indicated that miR-133a plays a role in diabetes-induced
cardiomyocyte hypertrophy; down-regulation alters gene
expression and mediates glucose-induced cardiomyocyte hyper-
trophy through SGK1 and IGFR128. However, van Rooij
et al.29 found that miR-133 did not produce any of the mor-
phological changes in cardiomyocytes associated with hyper-
trophic growth29.
Several other miRNAs have been found to be pro-hyper-
trophic including miR-208, 21, 18b, 195, 199, 23, 24, 27 and 9.
MiR-208 is cardiac speciﬁc and is shown to be necessary for
cardiomyocyte hypertrophy, ﬁbrosis and expression of
b-MHC in response to stress and hypothyroidism30. Mice
subjected to targeted deletion of miR-208 failed to undergo
stress-induced cardiac remodeling, hypertrophic growth and
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was shown to induce cardiac hypertrophy. During cardiac
hypertrophy, a reduction in the expression of a-MHC resulted
in diminished transcription of miR-208 and subsequently to
loss of its negative effects on thyroid hormone receptor
associated protein 1 (THRAP1) and to a blunted response
to pressure overload.
It is interesting to speculate on whether modulation of
miR-208 in vivo is a potentially useful therapeutic strategy in
cardiac hypertrophy. In support of this, Callis et al.31 reported
that overexpression of miR-208a in mouse heart was sufﬁcient to
induce hypertrophic growth resulting in pronounced repression
of the miR-208 regulatory targets, THRAP1 and myostatin, the
negative regulators of muscle growth and hypertrophy31.
Tatsuguchi et al.32 reported that inhibition of endogenous
miR-21 or miR-18b augmented hypertrophic growth whereas
introduction of functional miR-21 or miR-18b into cardio-
myocytes repressed it32. Despite this, the effect of miR-21 on
myocyte hypertrophy remains controversial. Cheng et al.33
found that miR-21 was strikingly up-regulated both in
hypertrophic mouse hearts and cultured neonatal hyper-
trophic cardiomyocytes and that modulating miR-21 expres-
sion via antisense-mediated depletion produced a signiﬁcantly
negative effect on cardiomyocyte hypertrophy33. Recently,
Patrick et al.34 reported that miR-21 was not essential for
pathological cardiac remodeling based on the fact that miR-
21-null mice did not display improved tolerance to a variety of
cardiac stressors compared to their wild-type littermates and
that inhibition of miR-21 failed to block stress-induced
cardiac remodeling34.
Overexpression of miR-195 during cardiac hypertrophy results
in pathological cardiac growth and heart failure in transgenic
mice29. MiR-199a is predominantly expressed in cardiomyocytes
where it maintains cell size and may play a role in the regulation
of cardiac hypertrophy. It is also conﬁrmed to target hypoxia-
inducible factor 1 alpha35. Previously, it was shown that miR-
23a, 27a and 24-2 are up-regulated during cardiac hypertrophy36
and that knockdown of miR-23a attenuates hypertrophy37.
Finally, miR-9 appears to regulate cardiac hypertrophy by
suppressing myocardin expression38.4. MiRNAs and cardiac ﬁbrosis
Cardiac ﬁbrosis is an established morphological feature of
structural myocardial remodeling that occurs in several car-
diac diseases including myocardial infarction, dilated hyper-
trophic cardiomyopathies and heart failure. The cellular basis
of ﬁbrosis is the adverse accumulation of collagens and other
extracellular matrix (ECM) proteins that increase the risk for
adverse cardiovascular events such as ventricular dysfunction
and arrhythmias. The etiology of the ﬁbrogenic cardiac
phenotype is still being elucidated but a small number of
studies have already demonstrated that altered expression of
several miRNAs in myocardial ﬁbrosis is associated with
ischemia or mechanical overload.
MiR-29 acts as a regulator of cardiac ﬁbrosis and represents
a potential therapeutic target for tissue ﬁbrosis in general39.
The miR-29 family targets a series of mRNAs that encode
proteins involved in ﬁbrosis, including multiple collagens,
ﬁbrillins and elastin. Down-regulation of miR-29 is therefore
predicted to repress the expression of some mRNAs andenhance the ﬁbrotic response. Indeed, such down-regulation
with anti-miRs in vitro and in vivo induces the expression of
collagens whereas overexpression of miR-29 in ﬁbroblasts
reduces it39. Down-regulation of miR-149 and up-regulation
of miR-21, 214 and 223 were shown to accompany down-
regulation of miR-2939, but the functional consequences of
these changes are unknown.
MiR-21 contributes to myocardial remodeling through
regulating the ERK-MAP kinase signaling pathway in cardiac
ﬁbroblasts during cardiac ischemia/reperfusion40 or in the
later stages of heart failure41. In vivo silencing of miR-21 by
a speciﬁc antagomir suppresses pathological ERK-MAP
kinase signaling and prevents cardiac dysfunction in a mouse
pressure-overload-induced disease model. MiR-21 regulates
ﬁbroblast survival and growth factor secretion that ultimately
control the extent of interstitial ﬁbrosis and cardiac hyper-
trophy41. Overall, these ﬁndings indicate that miR-21, like
miR-29, contributes to myocardial remodeling by affecting
cardiac ﬁbroblasts. Down-regulation of miR-21 could there-
fore be a beneﬁcial approach to block ﬁbroblast proliferation
in heart disease and thereby inhibit secondary cardiac
remodeling.
The potential importance of miR-133 in cardiac ﬁbrosis has
been underlined by reports that miR-133-a1 and miR-133-a2
knockout mice develop severe ﬁbrosis and heart failure42 and
that miR-133 and miR-590 are down-regulated in a canine
model of nicotine-induced atrial interstitial ﬁbrosis43,44.
Duisters et al.45 reported that knockdown of miR-133 or miR-
30 increased the level of connective tissue growth factor (CTGF)
and that overexpression of miR-133 or miR-30 decreased CTGF
levels accompanied by decreased production of collagens45. They
showed that CTGF was a direct target of these miRNAs because
they directly interacted with the 30 untranslated region of CTGF.
Another report showed that transgenic expression of miR-133a
prevented TAC-associated miR-133a down-regulation and
improved myocardial ﬁbrosis and diastolic function without
affecting the extent of hypertrophy46. Interestingly, mechanistic
studies in the canine model and in cultured atrial ﬁbroblasts
showed that the protective actions of miR-133 and miR-590 are
mediated through targeting TGF-b1 and TGF-b receptor type
II, respectively44.
In addition to cardiac ﬁbrosis, miRNAs are involved in the
ﬁbrotic process in other organs such as lung, kidney and
liver47. However, much research remains to be done to identify
which miRNAs have a direct role in the development of
ﬁbrosis, and which have altered expression secondary to
cardiac ﬁbrosis. Characterization of individual miRNAs or
miRNA expression proﬁles that are speciﬁcally associated
with myocardial ﬁbrosis will hopefully allow the development
of diagnostic tools and innovative therapies for ﬁbrogenic
cardiac diseases.5. MiRNAs and heart failure
As stated earlier, the heart responds to cardiac injury or
hemodynamic overload by activating a variety of intracellular
signaling pathways that provoke myocyte hypertrophy,
re-expression of embryonic genes and remodeling of the
extracellular matrix48. When the heart transits from adaptive
to maladaptive hypertrophy, heart failure occurs. The patho-
logical mechanism of heart failure is a result of the
De-li Dong, Bao-feng Yang4concomitant cross-talk between various deleterious and com-
pensatory signaling pathways, the balance between which
ultimately determines the pathological progression. Despite
signiﬁcant advances in the identiﬁcation of genes and signaling
pathways, the overall complexity of cardiac hypertrophic
remodeling suggests the involvement of additional global
regulatory signaling networks. A growing body of evidence
suggests that some miRNAs are involved in the process of
heart failure.
Cardiomyocyte-speciﬁc deletion of a gene or endonuclease,
such as dgcr8 and Dicer, which are required for microRNA
biogenesis and processing, leads to a dramatic fall in the level
of mature miRNAs and to left ventricular malfunction
progressing to a dilated cardiomyopathy and premature
lethality49,50. Sucharov et al.51 demonstrated that the expres-
sion of subsets of miRNAs was differentially regulated in
different heart failure models51. They found that inhibition of
miR-100, which was up-regulated in the failing heart, pre-
vented b-adrenoceptor (b-AR) mediated down-regulation of
the adult gene component of the fetal gene program. They also
suggested that overexpression of miR-133b attenuated b-AR
mediated changes in gene expression. van Rooij et al.29
showed that overexpression of individual stress-inducible
miRNAs was sufﬁcient to induce hypertrophic growth in
isolated cardiac myocytes and to provoke a dilated cardio-
myopathy in transgenic mice, suggesting that individual
miRNAs are sufﬁcient to provoke heart failure29. In their
other study30, they found that deletion of miR-208, a cardiac-
speciﬁc miRNA encoded by an intron in the gene that encodes
the a-myosin chain, protected against cardiac myocyte hyper-
trophy, up-regulated b-myosin heavy chain and produced
myocardial ﬁbrosis in response to thyroid signaling and
hemodynamic overload. They also showed that animals
deﬁcient in miR-208 did not ramp up cardiac expression of
b-myosin heavy chain in response to thyroid signaling.
MiR-199b is a direct calcineurin/NFAT target gene the
expression of which is increased in mouse and human heart
failure. miR-199b targets nuclear NFAT kinase dual-speciﬁ-
city tyrosine-(Y)-phosphorylation regulated kinase 1a
(Dyrk1a) in a process that constitutes a pathogenic feed
forward mechanism affecting calcineurin-responsive gene
expression52. In vivo inhibition of miR-199b by a speciﬁc
antagomir normalized Dyrk1a expression, reduced nuclear
NFAT activity and caused marked inhibition and even
reversal of hypertrophy and ﬁbrosis in mouse models of heart
failure. Naga Prasad et al.53 examined the alterations of
miRNA expression in human heart failure samples in order
to elucidate the global regulation of the signaling networks by
a unique miRNA pattern in end-stage human heart failure53.
They showed that eight miRNAs (miR-1, 214, 29b, 342, 7,
125, 378 and 181) were signiﬁcantly altered in dilated cardi-
omyopathy compared with non-failing controls. They also
identiﬁed two novel miRNAs (miR-7 and 378) that were
down-regulated in end-stage heart failure. Tijsen et al.54
identiﬁed a number of circulating miRNAs as putative
biomarkers of heart failure and showed that miR423-5p in
particular distinguished heart failure cases from non-heart
failure cases54.
Transfection of isolated adult rat cardiomyocytes with a set
of fetal miRNAs (miR-21, 129 and 212) resulted in hyper-
trophic morphological changes in neonatal cardiomyocytes
similar to those observed in the failing heart but transfectionof any one of the set produced only minor effects11. However,
many reports indicate that associations exist between single
miRNAs and heart failure and indeed that the pathological
changes in heart failure may require an alteration of the
miRNA environment.6. MiRNAs-based strategies for diagnostics and therapeutics
MiRNA expression has been shown to play a role in the
growth, development, function and stress responsivenesses of
the heart as well as in heart disease. The possibility of
exploiting miRNAs as diagnostic markers or therapeutic tools
has much to recommend it because of their speciﬁcity to their
targets in a particular cellular pathway.
MiRNAs show different expression patterns in the normal
and diseased heart and some data indicate that miRNA
expression may represent an efﬁcient diagnostic marker of
heart disease11,29. Identiﬁcation of abnormal miRNA levels in
tissue or plasma could certainly aid in early diagnosis and,
in fact, there is increasing evidence that circulating miRNAs
in various body ﬂuids are potential biomarkers of disease
diagnosis55–57. For example, certain miRNAs have been
proposed for screening colorectal cancer58 and for monitoring
pregnancy59. Recently, many miRNAs have been reported
to be potential biomarkers for cardiovascular disease and,
in particular, miR-208, miR-1 and miR-499 have been shown
to indicate the diagnosis and progression of myocardial
infarction60–62. In the case of miR-208, its plasma concentration
increased in isoproterenol-induced myocardial injury and was
well correlated with the plasma concentration of cTnI, the
classical marker of myocardial injury60. For miR-1, the plasma
level was signiﬁcantly higher in patients with acute myocardial
infarction (AMI) compared with non-AMI subjects and the level
dropped to normal on discharge following medication61. For
miR-499, plasma concentrations were signiﬁcantly increased in
patients with acute myocardial infarction but were below the
detection limit in other patient groups62.
Other circulating miRNAs have been proposed as sensitive
and informative biomarkers for the diagnosis of heart failure.
MiR423-5p is speciﬁcally enriched in the blood of heart failure
patients but not in healthy people indicating that certain
miRNAs are not only diagnostic predictors of heart failure but
also a means of distinguishing clinical heart failure from other
diseases54. The plasma concentration of miR-126 has also
been proposed as a biomarker of heart failure63. Moreover,
miRNAs are more sensitive than mRNAs in detecting
end-stage heart failure64. These and other studies reveal the
potential of miRNAs in assessing the risk of certain kinds
of disease and in evaluating the efﬁcacy of treatment. The
development of miRNAs as biomarkers for cardiovascular
diseases is still in its infancy and, no doubt, will remain an
active ﬁeld for many years yet.
Identiﬁcation of speciﬁc miRNAs and target genes that
contribute to adult cardiac pathology is likely to provide new
therapeutic targets. In the classical course of drug discovery, it
takes many years to identify such targets, devise and execute
accurate screening methods, and eventually develop the
molecules affecting those targets as therapeutic agents.
However, miRNAs are not likely to require such a prolonged
process since they can be efﬁciently manipulated to tune gene
regulation and are more amenable to incorporation in drug
Figure 1 Current understanding of the role of microRNAs in
cardiac hypertrophy, myocardial ﬁbrosis and heart failure.
Thrap1: thyroid hormone receptor associated protein 1; Cdc42:
cell division cycle 42; Nelf-A: negative elongation factor A;
WHSC2: Wolf–Hirschhorn syndrome candidate 2; IGFR1: insu-
lin-like growth factor receptor 1; SGK1: serum- and glucose-
regulated kinase; RasGAP: Ras GTPase-activating protein; Cdk9:
cyclin-dependent kinase 9; Rheb: Ras homolog enriched in brain;
MuFR1: the muscle speciﬁc ring ﬁnger protein 1; HIF1: hypoxia-
inducible factor 1; CTGF: connective tissue growth factor; PTEN:
tensin homolog; MMP-2: matrix metalloprotease-2; Spry1: spro-
uty homolog 1; a-MHC: alpha-myosin heavy chain; Dyrk1a:
dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated kinase 1a.
Role of microRNAs in heart disease 5delivery systems because of their small size65,66. Furthermore,
miRNAs are predicted to have multiple mRNA targets67,
some of which appear to work in concert to control a common
pathway or biological function. However, this can also be seen
as a major disadvantage because of its propensity to cause side
effects. Although there are several approaches to change
miRNA levels in vivo and in vitro as exempliﬁed in numerous
gain-of-function and loss-of-function studies, a detailed under-
standing of miRNA biology and function pertaining to the
heart remains some way off.
Exogenous miRNAs, either synthetic or constructed in
virus vectors, have been used to restore the decreased levels
that accompany certain cardiovascular diseases and thereby
retard the associated pathological process24,41. Generally,
these miRNAs are double-stranded and have the same
sequence as endogenous miRNAs. One technique to increase
the cellular level of a speciﬁc miRNA is through the use of a
miRNA mimic, which utilizes synthetic nucleic acids to bind
to target mRNAs and elicit post-transcriptional regulatory
effects. The double-stranded structure enables efﬁcient recog-
nition and loading into RISC to elicit miRNA action. This
strategy can potentially repress the target gene at the post-
transcriptional level with minimal effects on the mRNA level.
These constructs are analogous to siRNA molecules and have
been successfully utilized in vitro. Efﬁcacy in vivo remains to be
demonstrated.
Efﬁcient reduction in the level of speciﬁc miRNAs associated
with a particular disease should be therapeutically advanta-
geous. Inhibiting miRNAs expression can be achieved using
antisense inhibitor oligonucleotides (AMO) designed to fully
complement their target miRNAs in order to degrade them.
Besides being potentially therapeutic, the application of AMOs
is a popular method for studying miRNA function. Further-
more, antagomirs based on cholesterol conjugated oligonucleo-
tides have been used to facilitate cellular uptake and resolve the
delivery problem faced by AMOs. Antagomirs which target a
speciﬁc miRNA or disrupt the binding between an miRNA and
its target represent a potentially effective way to inactivate
pathological miRNAs. The ﬁrst successful mammalian in vivo
study using such an antagomir aimed to inhibit a liver-speciﬁc
miR-12266. Further studies have since attempted to modify
cellular uptake using high-density lipoproteins68, 20-O-methoxy-
ethyl phosphorothioate65, and locked-nucleic-acid-modiﬁed oli-
gonucleotides69 that were subsequently tested in non-human
primates70. With respect to the heart, in vivo inhibition of
miR-133 and miR-29 with antagomirs in mice has implicated
their participation in cardiac hypertrophy and cardiac ﬁbrosis,
respectively10,39. Antagomirs are powerful tools to silence
speciﬁc miRNAs in vivo and may represent a therapeutic
strategy for silencing miRNAs in disease66.
Another way to interfere with miRNA–mRNA interactions
is through competitive inhibition of miRNA using ‘‘miRNA
sponges’’. These can be expressed in cells as transcripts of
strong promoters containing multiple, tandem binding sites to
a related miRNA71. Comparable to sponges, miRNA erasers
use only two copies of a perfectly complementary antisense
sequence of a miRNA72. Recently, this approach has been
tested in Drosophila in an attempt to understand the factors
that contribute to the spatiotemporal speciﬁcity of miRNAs73.
Research into the role of miRNAs in human heart disease
holds great promise for future therapeutic applications. How-
ever, developing miRNAs into therapeutic agents facessigniﬁcant challenges associated with their drug delivery and
duration of action. Although local delivery to the heart
through direct injection or via a catheter or coated stent
would avoid these problems, its clinical feasibility remains to
be determined.
7. Conclusions
MiRNAs have emerged as a novel class of key regulators in a
variety of cardiovascular diseases including cardiac hyper-
trophy, ﬁbrosis and heart failure. We summarize the current
understanding of microRNAs in cardiac hypertrophy, myo-
cardial ﬁbrosis and heart failure in Fig. 1. MicroRNAs
represent potential pharmacological targets since down- or
up-regulation of a particular miRNA is enough to cause a
speciﬁc cardiovascular disease and correcting their aberrant
expression can reverse the pathological process. Ongoing
efforts to identify the targets of speciﬁc miRNAs involved in
De-li Dong, Bao-feng Yang6the cardiovascular system will increase our understanding of
the molecular mechanisms underlying disease processes. How-
ever, the fact that a single miRNA can control hundreds of
distinct target genes and potentially affect many cellular
pathways means that achieving a full understanding of
miRNA-mediated molecular networks in the heart is a
signiﬁcant challenge. Thus the routine application of miRNAs
in the clinic remains a rather distant goal.References
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